Sanofi-Aventis has opened its first R&D center in China, which it hopes will allow it to tap the burgeoning Chinese pharmaceuticals market. The French drugmaker is also pursuing R&D activities in Russia, South Korea and India as part of its ongoing strategy to expand in biologics, generics and emerging markets. R&D chief Marc Cluzel says in a statement that the new R&D center will help Sanofi develop therapies specifically for the Chinese population.
"We hope to become the first multinational drug company that completes truly home-grown research activities and will cooperate with local partners," said Thomas Kelly, VP of Sanofi's China operations, according to the Shanghai Daily.
- read the report on Sanofi